## **Guy A Higgins**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2484703/publications.pdf

Version: 2024-02-01

201674 206112 2,598 49 27 48 citations g-index h-index papers 49 49 49 1989 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	2
2	Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats. Neuropharmacology, 2022, , 109150.	4.1	3
3	5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence. Progress in Brain Research, 2021, 259, 229-263.	1.4	3
4	Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. Frontiers in Pharmacology, 2021, 12, 640241.	3.5	31
5	Contrasting effects of d-amphetamine and atomoxetine on measures of impulsive action and choice. Pharmacology Biochemistry and Behavior, 2021, 207, 173220.	2.9	4
6	Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential., 2020, 205, 107417.		52
7	Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research. Frontiers in Pharmacology, 2020, $11$ , $427$ .	3.5	17
8	Effects of 5-HT2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour. Neuropharmacology, 2020, 170, 108064.	4.1	20
9	Evaluation of Selective 5-HT <sub>2C</sub> Agonists in Acute Seizure Models. ACS Chemical Neuroscience, 2019, 10, 3284-3295.	3.5	23
10	Preclinical evidence for combining the 5â€< scp>HT <sub>2C</sub> receptor agonist lorcaserin and varenicline as a treatment for nicotine dependence. Addiction Biology, 2019, 24, 376-387.	2.6	9
11	Effects of the NMDA receptor antagonists dizocilpine and Ro 63-1908 on delay-discounting and risky decision-making in a gambling task. Behavioural Brain Research, 2018, 348, 201-210.	2.2	7
12	Effects of 5-HT1A, 5-HT2A and 5-HT2C receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate. Psychopharmacology, 2017, 234, 889-902.	3.1	8
13	<sup>18</sup> F-FPP: A PET Ligand for the 5-HT <sub>2C</sub> Receptor?. ACS Chemical Neuroscience, 2017, 8, 904-907.	3.5	3
14	Studies To Examine Potential Tolerability Differences between the 5-HT <sub>2C</sub> Receptor Selective Agonists Lorcaserin and CP-809101. ACS Chemical Neuroscience, 2017, 8, 1074-1084.	3.5	8
15	Role of impulsivity and reward in the anti-obesity actions of 5-HT <sub>2C</sub> receptor agonists. Journal of Psychopharmacology, 2017, 31, 1403-1418.	4.0	30
16	Rodent Test of Attention and Impulsivity: The 5â€Choice Serial Reaction Time Task. Current Protocols in Pharmacology, 2017, 78, 5.49.1-5.49.34.	4.0	33
17	Pharmacological Modulation of 5-HT2C Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice. Neuropsychopharmacology, 2017, 42, 2178-2187.	5.4	24
18	Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment. Behavioural Brain Research, 2016, 311, 1-14.	2.2	34

#	Article	IF	Citations
19	Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists. Psychopharmacology, 2016, 233, 2841-2856.	3.1	35
20	The 5-HT 2C receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology, 2016, 101, 237-245.	4.1	59
21	Characterization of the 5â€HT <sub>2C</sub> receptor agonist lorcaserin on efficacy and safety measures in a rat model of dietâ€induced obesity. Pharmacology Research and Perspectives, 2015, 3, e00084.	2.4	25
22	The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine. ACS Chemical Neuroscience, 2015, 6, 1231-1240.	3.5	30
23	Therapeutic Potential of 5-HT <sub>2C</sub> Receptor Agonists for Addictive Disorders. ACS Chemical Neuroscience, 2015, 6, 1071-1088.	3.5	75
24	Enduring attentional deficits in rats treated with a peripheral nerve injury. Behavioural Brain Research, 2015, 286, 347-355.	2.2	25
25	Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats. Behavioural Pharmacology, 2014, 25, 775-783.	1.7	20
26	Impulsive action in the 5-choice serial reaction time test in 5-HT2C receptor null mutant mice. Psychopharmacology, 2013, 226, 561-570.	3.1	35
27	From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends in Pharmacological Sciences, 2013, 34, 560-570.	8.7	90
28	Silexan, an essential oil from flowers of Lavandula angustifolia, is not recognized as benzodiazepine-like in rats trained to discriminate a diazepam cue. Phytomedicine, 2013, 20, 172-177.	5.3	16
29	Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology, 2013, 226, 475-490.	3.1	51
30	Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology, 2012, 62, 2288-2298.	4.1	65
31	The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination, and Reinstatement: Relationship to Feeding Behavior and Impulse Control. Neuropsychopharmacology, 2012, 37, 1177-1191.	5.4	122
32	Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT2C receptor stimulation and 5-HT2A receptor blockade. Neuropharmacology, 2011, 61, 468-477.	4.1	90
33	Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology, 2010, 207, 513-527.	3.1	29
34	Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement. Pharmacology Biochemistry and Behavior, 2010, 97, 170-178.	2.9	26
35	Characterizing the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. Neuropharmacology, 2009, 57, 259-267.	4.1	71
36	Rodent Model of Attention: The 5â€Choice Serial Reaction Time Task. Current Protocols in Pharmacology, 2008, 41, Unit5.49.	4.0	28

#	Article	IF	CITATIONS
37	Serotonin receptors as potential targets for modulation of nicotine use and dependence. Progress in Brain Research, 2008, 172, 361-383.	1.4	50
38	The 5-HT2C Receptor Agonist Ro60-0175 Reduces Cocaine Self-Administration and Reinstatement Induced by the Stressor Yohimbine, and Contextual Cues. Neuropsychopharmacology, 2008, 33, 1402-1412.	5.4	107
39	Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology, 2007, 195, 223-234.	3.1	185
40	Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology, 2005, 179, 85-98.	3.1	66
41	Injection of the 5-HT2C Receptor Agonist Ro60-0175 into the Ventral Tegmental Area Reduces Cocaine-Induced Locomotor Activity and Cocaine Self-Administration. Neuropsychopharmacology, 2004, 29, 308-318.	5.4	122
42	The Opioid Receptor Like-1 Receptor Agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro [4.5] decan-4-one) Produces a Discriminative Stimulus in Rats Distinct from That of a $\hat{l} \not / 4$ , $\hat{l}^0$ , and $\hat{l}'$ Opioid Receptor Agonist Cue. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 652-658.	2.5	21
43	The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology, 2003, 170, 309-319.	3.1	162
44	Serotonin and drug reward: focus on 5-HT2C receptors. European Journal of Pharmacology, 2003, 480, 151-162.	3.5	147
45	Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacology Biochemistry and Behavior, 2002, 71, 615-625.	2.9	129
46	Differential Effects of the 5-HT2A Receptor Antagonist M100,907 and the 5-HT2C Receptor Antagonist SB242,084 on Cocaine-induced Locomotor Activity, Cocaine Self-administration and Cocaine-induced Reinstatement of Responding. Neuropsychopharmacology, 2002, 27, 576-86.	5.4	210
47	Assessing a vigilance decrement in aged rats: effects of pre-feeding, task manipulation, and psychostimulants. Psychopharmacology, 2002, 164, 33-41.	3.1	75
48	Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: influence of apomorphine and phencyclidine pretreatment. Journal of Psychopharmacology, 1994, 8, 148-156.	4.0	73
49	Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. Psychopharmacology, 1991, 105, 322-328.	3.1	48